180 Views | 79 Downloads
Correspondence: elizerm_vanallen@dfci.harvard.edu (E.M.V.A.), sramachandran@brown.edu (S.R.)
Conceptualization, S.R., S.S., and E.M.V.A.; Methodology, S.H.A., A.G., M.X.H., M.A.R., and S.S.; Formal Analysis, M.X.H., M.A.R., and S.S.; Writing, S.R., M.A.R., S.S., and E.M.V.A.; Supervision, S.R. and E.M.V.A.
We thank the patients who contributed to the TCGA study. The results published here are based upon data generated by the TCGA Research Network.
Disclosures: E.M.V.A. serves in an advisory/consulting role for the following corporations: Tango Therapeutics, Genome Medical, Invitae, Illumina, Ervaxx, and Janssen. He receives research support from Novartis and Bristol-Myers Squibb.
He owns equity in Tango Therapeutics, Genome Medical, Syapse, Microsoft, and Ervaxx. He has received travel reimbursement from Roche/Genentech. He holds institutional patents filed on ERCC2 mutations and chemotherapy response, chromatin mutations and immunotherapy response, and methods for clinical interpretation.
he study was supported by the following funding sources: NSF CAREER DBI-1452622 (S.R.); NIH R01 GM118652 (S.R.); NIH U01 CA217875 (M.A.R.); Brown University Sidney Frank Fellowship (S.S.); PCF-V Foundation Challenge Award (E.M.V.A.); NIH R01 CA227388 (E.M.V.A.); and NIH U01 CA233100 (E.M.V.A.).
© 2020 The Author(s).